hemophilia A

qfitlia-for-hemophilia-treatment

Apr 07, 2025

Sanofi’s Qfitlia Enters the Hemophilia Market—What Sets It Apart?

pharma-news-for-beam-astrazeneca-sanofi

Apr 01, 2025

Sanofi’s Qfitlia Becomes First FDA-Approved Therapy for Hemophilia A or B; FDA Approves AstraZeneca’s IMFINZI as First Perioperative Immunotherapy for Bladder Cancer; Beam Therapeutics’ BEAM-302 for AATD Receives FDA Clearance; AstraZeneca’s CALQUENCE Combo Greenlit in EU for Mantle Cell Lymphoma; Ionis’ WAINZUA Wins EU Approval for Hereditary Transthyretin Amyloidosis

role-of-plasma-protein-therapeutics

Oct 23, 2024

Plasma Proteins Therapeutics: Transforming Treatment in Hematology and Beyond

biomarins-roctavian-first-hemophilia-a-gene-therapy

Jul 14, 2023

The Future is Here: BioMarin’s Roctavian First Hemophilia A Gene Therapy Paving the Way for a Cure

Pharma News for BioMarin, CellTrans, Genenta, GSK

Jul 04, 2023

First Gene Therapy for Severe Hemophilia A; FDA Approves CellTrans’s Type 1 Diabetes Cellular Therapy; FDA Approve Amneal’s Parkinson’s Drug Over Safety Concerns; NLS Pharmaceutics’s Phase III Clinical Trials of Quilience; Genenta Science’s Temferon for the Treatment of Glioma; FDA Fast Track Designation to GSK’s Gonorrhea Drug

cell-and-gene-therapies-in-rare-disorders-outlook

Jun 09, 2023

Cell and Gene Therapies in Rare Disorders: From Rarity to Recovery

Hemophilia A Market Forecast and Assessment

Nov 07, 2022

Roche’s HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape

Pharma News for Sangamo, Santen, and Eli Lilly

Sep 27, 2022

Daiichi Sankyo’s Ezharmia; Pfizer & Sangamo Hemophilia A Gene Therapy Trial; Approval for Fennec’s Pedmark; FDA Approves UBE and Santen’s OMLONTI; EC Approves AstraZeneca’s Tezspire; FDA Approves Selpercatinib; FDA Grants Accelerated Approval to Eli Lilly’s Retevmo; GSK & Spero Announce Exclusive License Agreement

aav-vectors-in-gene-therapy-landscape

Aug 19, 2022

AAV Vectors in Gene Therapy: How Recent Clinical Advances are Unraveling New Potentials?

Pharma News for AbbVie and Sobi

Jul 12, 2022

Novo Nordisk’s Concizumab for Hemophilia; AbbVie Ends its Alliance with Alector; ADC Therapeutics and Sobi Enters in Exclusive Licensing Deal; BMS’ Opdivo Gets NHS Use; Merck to Acquire Seagen; FDA Priority Review to Roche’s Lunsumio; AstraZeneca to Acquire TeneoTwo; FDA Orphan Drug Designation to PBI-200

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper